Key result
Transcatheter aortic valve replacement was presented as a viable, minimally invasive treatment for aortic stenosis 24 years after cardiac transplantation.
Why the study?
Improved survival after cardiac transplantation has led to late complications such as aortic stenosis, where TAVR may offer a minimally invasive alternative to high-risk reoperative sternotomy.
Case Report (n=1)
TAVR can be utilized as a minimally invasive treatment for late-onset aortic stenosis in high-risk patients with a history of cardiac transplantation.
May offer a less invasive option late after transplant; hypothesis-generating and leaves open need for prospective validation.
As patient survival after cardiac transplantation has improved over the course of the last several decades, clinicians are now faced with late complications. This includes aortic stenosis which, traditionally, has been treated with reoperative sternotomy and aortic valve replacement. Transcather aortic valve replacement (TAVR) offers a minimally invasive alternative in this high-risk population. A small but growing number of cases of TAVR after heart transplantation in high-risk patients have been reported in the last 10 years; we now present a case of aortic valve replacement via a transcatheter approach 24 years after cardiac transplantation.
No takes yet. Share an insight, caveat, or question.
Wallen et al. (2020) conducted a case report in Aortic stenosis after cardiac transplantation (n=1). Transcatheter aortic valve replacement (TAVR) was evaluated. Transcatheter aortic valve replacement was presented as a viable, minimally invasive treatment for aortic stenosis 24 years after cardiac transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: